The globalimmunoassay marketsize was estimated at USD 28.05 billion in 2025 and is projected to reach USD 40.25 billion by 2033, growing at a CAGR of 4.63% from 2026 to 2033. The market is primarily driven by the increasing demand for precision medicine across healthcare systems worldwide. As healthcare providers focus on delivering personalized treatment strategies, immunoassays have become essential diagnostic tools for identifying disease-specific biomarkers and monitoring patient responses to therapies.
These assays play a critical role in tailoring treatments to individual patients by detecting biological markers that help predict responses to specific therapeutic interventions. The growing prevalence of chronic diseases, advancements in diagnostic technologies, and rising adoption of personalized healthcare approaches are further contributing to the expansion of the immunoassay market.
Key Market Trends Insights
- The North America immunoassay industry held the largest share of 47.27% of the global market in 2025. The region's dominance can be attributed to its well-established healthcare infrastructure, high healthcare expenditure, strong presence of leading diagnostic companies, and increasing utilization of advanced laboratory testing technologies. Furthermore, ongoing investments in research and development activities and growing awareness regarding early disease detection continue to support market growth across North America.
- The immunoassay industry in the U.S. is expected to grow significantly over the forecast period. Factors such as increasing demand for advanced diagnostic solutions, rising prevalence of infectious and chronic diseases, expanding adoption of precision medicine, and continuous technological innovations in immunoassay platforms are expected to drive market expansion. In addition, favorable reimbursement policies and strong government support for healthcare innovation are contributing to the country's market growth.
- By product, the reagents kits segment held the highest market share of 66.22% in 2025. The segment's leading position is primarily driven by the recurring demand for reagents and consumables required for routine diagnostic testing. The growing volume of laboratory tests, increasing use of immunoassay-based diagnostics, and continuous introduction of specialized testing kits for various diseases are supporting the sustained growth of this segment.
- By technology, the enzyme immunoassays (EIA) segment held the largest market share in 2025. Enzyme immunoassays are widely used due to their high sensitivity, specificity, reliability, and cost-effectiveness in detecting a broad range of biomarkers. Their extensive application in clinical diagnostics, disease screening, and laboratory research continues to strengthen the segment's market position.
- By application, the infectious disease segment held the largest market share in 2025. The increasing burden of infectious diseases, growing demand for rapid and accurate diagnostic testing, and rising focus on disease surveillance and outbreak management are key factors driving the segment's dominance. Immunoassays remain widely utilized for the detection and monitoring of various infectious conditions, supporting timely diagnosis and effective patient management.
Looking for more specific insights? Customize this report to suite your business needs
Key Companies Market Share Insights
Leading companies operating in the immunoassay industry, including Abbott, Siemens Healthineers, Danaher Corporation (Beckman Colter), bioMrieux, QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Roche, Becton, Dickinson and Company, and Thermo Fisher Scientific, are actively focusing on technological innovation and portfolio expansion to strengthen their market position. Companies are increasingly adopting strategies such as product launches, strategic collaborations, geographic expansion, regulatory approvals, and mergers and acquisitions to enhance immunodiagnostic capabilities and expand access to advanced testing solutions. In addition, growing investments in automated immunoassay systems, biomarker-based diagnostics, point-of-care testing, and AI-integrated laboratory technologies are intensifying competition and supporting the continued growth of the global market.
Key Immunoassay Companies:
- Abbott
- Siemens Healthineers
- Danaher Corporation (Beckman Coulter)
- bioMrieux SA
- Quidel Corporation
- Sysmex Corporation
- Ortho Clinical Diagnostics
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Becton, Dickinson, and Company
- Thermo Fisher Scientific, Inc.
Grand View Research offers
- Focused market intelligence reports on specific geographies or high-growth segments.
- Extended forecast timelines for long-term planning.
- Competitor Benchmarking and Supply Chain Analysis
- Inclusion of regulatory and policy assessments.
- Inclusion of custom data models, KPIs, or applications unique to your business
- Specific high-impact Data Decks and Tables to support effective decision making
- And much more
Looking for a report customized to your requirements?Explore our Custom Research Offering
